Market Overview:
The global gemcitabine HCl market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and growing awareness about cancer treatments. Based on type, the global gemcitabine HCl market is segmented into more than or equal to 98% and < 98%. The more than or equal to 98% segment is expected to account for a larger share of the market during the forecast period. This can be attributed to its higher efficacy compared with other types of gemcitabine HCl. Based on application, the global gemcitabine HCl market is segmented into injection and application II. The injection segment is expected to account for a larger share of the market during the forecast period. This can be attributedto its higher usage in cancer treatment compared with other applications.
Product Definition:
Gemcitabine HCl is an anticancer agent that is used to treat various types of cancer, including pancreatic cancer, breast cancer, and lung cancer. It works by inhibiting the growth of tumor cells. Gemcitabine HCl is important because it can be used to treat a variety of cancers and it is relatively safe and effective.
More than or euqal to 98%:
Gemcitabine HCl is used in the treatment of pancreatic cancer and has a more than 90% success rate. The drug was approved by the U.S. FDA in 2001 for use as a first-line therapy for pancreatic cancer, which has few curative therapies and is generally treated with surgical procedures followed by chemotherapy or radiotherapy.
< 98%:
The < 98% is used as a diluent in Gemcitabine HCl, which is an intravenous drug used for the treatment of cancer. The major reason for its usage is to reduce the concentration of doxorubicin, a cytotoxic agent that interferes with cell respiration and causes damage to DNA and RNA.
Application Insights:
Injectable formulations of gemcitabine are used for the treatment of pancreatic cancer, lung and breast cancer, and liver cancer. Application II accounted for the largest revenue share in 2017 owing to its usage in various oncology indications such as pancreatic, lung, breast and liver cancers. The injectable form is more effective than the oral form in treating these types of cancers.
The oral formulation is approved by U.S FDA for use against non-small cell lung carcinoma (NSCLC) which makes it a suitable alternative togemcitabine injection therapy across North America region due to high unmet medical needs regarding treatment options other than surgery & chemotherapy among patients diagnosed with this type of tumor.
Regional Analysis:
North America dominated the global gemcitabine hcl market in 2017. The region is expected to maintain its dominance over the forecast period as well. This can be attributed to favorable government initiatives, increasing awareness about cancer treatment options, and availability of highly skilled physicians & healthcare professionals in this region. In addition, high adoption of advanced technology for research & development activities is also contributing towards regional growth.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to presence of a large patient pool and unmet clinical needs regarding various types of cancers such as liver & gastrointestinal tract cancers that are suitable for gemcitabine based chemotherapy treatment options along with other factors such as rising medical tourism industry and demand for cost-effective treatments from emerging economies like China & India are driving regional market growth in Asia Pacific region.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the gemcitabine HCl market. According to a study by the World Health Organization (WHO), it is estimated that there will be around 18 million new cases of cancer and 9.6 million deaths due to cancer in 2018. This number is expected to rise significantly in the coming years, thereby driving the demand for gemcitabine HCl drugs.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about early diagnosis and treatment of cancers, which is propelling the demand for gemcitabine HCl drugs. In addition, governments are also investing in initiatives to raise awareness about various types of cancers and their treatments, which will further boost the growth of this market during forecast period.
- Technological advancements in chemotherapy: The technological advancements in chemotherapy are resulting in better outcomes with fewer side effects, thereby driving demand for gemcitabine HCl drugs globally. For instance, researchers at University College London have developed a new drug delivery system that can target tumors more effectively while reducing damage to healthy tissues nearby – this could lead to increased adoption rates of Gemzar® (gemcitabine hydrochloride) as well as other chemotherapies containing gemcitabine across different regions worldwide during forecast period .
- . Growing aging population: The growing aging population across globe is another key factor fuelling growth Gemzar®
Scope Of The Report
Report Attributes
Report Details
Report Title
Gemcitabine HCl Market Research Report
By Type
More than or euqal to 98%, < 98%
By Application
Injection, Application II
By Companies
Sun Pharmaceutical Industries, Tapi Teva, Shilpa Medicare, Huachu Industrial, Jinkang Pharmaceutical Technology, Jierui Pharmaceutical, HISUN
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Gemcitabine HCl Market Report Segments:
The global Gemcitabine HCl market is segmented on the basis of:
Types
More than or euqal to 98%, < 98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Injection, Application II
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sun Pharmaceutical Industries
- Tapi Teva
- Shilpa Medicare
- Huachu Industrial
- Jinkang Pharmaceutical Technology
- Jierui Pharmaceutical
- HISUN
Highlights of The Gemcitabine HCl Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- More than or euqal to 98%
- < 98%
- By Application:
- Injection
- Application II
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gemcitabine HCl Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gemcitabine HCl is a chemotherapy drug used to treat cancer. It works by stopping the growth of cancer cells. Gemcitabine HCl is usually given as an injection into a vein, but it can also be taken by mouth.
Some of the major companies in the gemcitabine hcl market are Sun Pharmaceutical Industries, Tapi Teva, Shilpa Medicare, Huachu Industrial, Jinkang Pharmaceutical Technology, Jierui Pharmaceutical, HISUN.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gemcitabine HCl Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gemcitabine HCl Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gemcitabine HCl Market - Supply Chain
4.5. Global Gemcitabine HCl Market Forecast
4.5.1. Gemcitabine HCl Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gemcitabine HCl Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gemcitabine HCl Market Absolute $ Opportunity
5. Global Gemcitabine HCl Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gemcitabine HCl Market Size and Volume Forecast by Type
5.3.1. More than or euqal to 98%
5.3.2. < 98%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gemcitabine HCl Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gemcitabine HCl Market Size and Volume Forecast by Application
6.3.1. Injection
6.3.2. Application II
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gemcitabine HCl Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gemcitabine HCl Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gemcitabine HCl Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gemcitabine HCl Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gemcitabine HCl Demand Share Forecast, 2019-2026
9. North America Gemcitabine HCl Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gemcitabine HCl Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gemcitabine HCl Market Size and Volume Forecast by Application
9.4.1. Injection
9.4.2. Application II
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gemcitabine HCl Market Size and Volume Forecast by Type
9.7.1. More than or euqal to 98%
9.7.2. < 98%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gemcitabine HCl Demand Share Forecast, 2019-2026
10. Latin America Gemcitabine HCl Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gemcitabine HCl Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gemcitabine HCl Market Size and Volume Forecast by Application
10.4.1. Injection
10.4.2. Application II
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gemcitabine HCl Market Size and Volume Forecast by Type
10.7.1. More than or euqal to 98%
10.7.2. < 98%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gemcitabine HCl Demand Share Forecast, 2019-2026
11. Europe Gemcitabine HCl Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gemcitabine HCl Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gemcitabine HCl Market Size and Volume Forecast by Application
11.4.1. Injection
11.4.2. Application II
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gemcitabine HCl Market Size and Volume Forecast by Type
11.7.1. More than or euqal to 98%
11.7.2. < 98%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
1110.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gemcitabine HCl Demand Share, 2019-2026
12. Asia Pacific Gemcitabine HCl Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gemcitabine HCl Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gemcitabine HCl Market Size and Volume Forecast by Application
12.4.1. Injection
12.4.2. Application II
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gemcitabine HCl Market Size and Volume Forecast by Type
12.7.1. More than or euqal to 98%
12.7.2. < 98%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gemcitabine HCl Demand Share, 2019-2026
13. Middle East & Africa Gemcitabine HCl Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gemcitabine HCl Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gemcitabine HCl Market Size and Volume Forecast by Application
13.4.1. Injection
13.4.2. Application II
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gemcitabine HCl Market Size and Volume Forecast by Type
13.7.1. More than or euqal to 98%
13.7.2. < 98%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gemcitabine HCl Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gemcitabine HCl Market: Market Share Analysis
14.2. Gemcitabine HCl Distributors and Customers
14.3. Gemcitabine HCl Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sun Pharmaceutical Industries
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Tapi Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shilpa Medicare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Huachu Industrial
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Jinkang Pharmaceutical Technology
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Jierui Pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. HISUN
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook